Ventas Reports 2019 Second Quarter Results

CHICAGO–(BUSINESS WIRE)–$VTR–Ventas, Inc. (NYSE: VTR) today announced its results for the second quarter ended June 30, 2019.

“Ventas had a highly productive second quarter as we delivered strong results, executed on our near term development pipeline in our exciting university-based research & innovation business, and captured accretive and attractive external investments, including with Le Groupe Maurice,” said Debra A. Cafaro, Ventas Chairman and CEO.

“Building on our strong momentum in 2019, we are increasing our guidance for the year. With our powerful combination of a large, diverse high quality portfolio, which is benefitting from strong demand; our best in class partners; and our collaborative, experienced and results-oriented team, we are well positioned to meet our objectives in 2019 and pivot to growth in 2020. We look forward to the positive impact of an upcycle in senior housing from the expected combination of increasing demographic demand and reduced community openings, the completion and lease-up of our promising R&I development assets, growth in our core portfolio and accretive investment activity,” Cafaro added.

Second Quarter 2019 Company Performance

  • Net income attributable to common stockholders per diluted share for second quarter 2019 was $0.58 compared to $0.46 in the same period in 2018. The year-over-year increase from 2018 was due principally to growth in second quarter 2019 property-level operating income and a non-cash income tax benefit in the quarter. The second quarter 2019 also benefitted from cash natural disaster recoveries, the recognition of cash profit on warrants held in the Company’s Research & Innovation (“R&I”) business, and a $21 million second quarter 2018 non-cash expense (the “2018 Non-Cash Brookdale Expense”) incurred in connection with a mutually beneficial Brookdale Senior Living, Inc. (“Brookdale”) lease extension. These benefits were partially offset by lower gains on real estate asset dispositions and lower interest income from loans and investments in the second quarter 2019 mainly due to the second quarter 2018 full payoff of the Ardent Health Services (“Ardent”) loans and related fee recognition.
  • Reported Funds from Operations per share, as defined by the National Association of Real Estate Investment Trusts (“Nareit FFO”) was $1.13 compared to $0.98 in the same period in 2018. The change from 2018 results was due to the factors described above, adjusted to exclude the impact of lower gains from the sale of real estate assets in the second quarter of 2019.
  • Normalized Funds from Operations (“FFO”) per share for second quarter 2019 was $0.97 compared to $1.08 in 2018. The change from 2018 was primarily the result of the second quarter 2018 full payoff of the Ardent loans and recognition of related fees as described above. The second quarter 2019 non-cash tax benefit, cash natural disaster recoveries and the 2018 Non-Cash Brookdale Expense are excluded from the Company’s normalized FFO results for their respective periods.

Second Quarter 2019 Portfolio Performance

  • For the second quarter 2019, the Company’s quarterly same-store total property portfolio (1,104 assets) cash net operating income (“NOI”) was in line with expectations and rose 0.3 percent compared to the same period in 2018. Excluding the impact of a cash fee of $2.5 million received by the Company in the second quarter of 2018 from Brookdale, the Company’s portfolio grew same-store NOI 0.9 percent. Reported same-store cash NOI performance by segment for the second quarter 2019 is as follows:

 

 

 

 

 

 

 

Same-Store Cash NOI

 

 

 

Q2 2019

 

 

 

Reported Growth

 

 

 

 

Triple-Net (“NNN”)

 

 

1.5%

Senior Housing Operating Properties (“SHOP”)

 

 

(2.9%)

Office

 

 

2.9%

Total Company

 

 

0.3%

  • Second quarter year-over-year changes in the Company’s same-store property results were driven by:

    • NNN portfolio: Growth was primarily the result of net in-place lease escalations. Excluding the 2018 $2.5 million cash fee noted above from Brookdale, the NNN portfolio grew 2.9 percent.
    • SHOP portfolio: As expected, same-store SHOP performance was driven by the impact of continued 2019 elevated new community openings in select markets, which affected rate and occupancy. In addition, average occupancy compared to last year trended in accordance with the Company’s expectations. Despite significant new openings, absorption growth was robust and the positive trend of lower new construction starts continued during the quarter.
    • Office portfolio: Growth was led by excellent performance in the Company’s university-based R&I properties and complemented by solid growth in the Company’s medical office building (“MOB”) portfolio, which is benefitting from the implementation and success of operational and sustainability initiatives.

2019 Investment Highlights

The Company demonstrated momentum in its accretive external investment activity, announcing nearly $3.5 billion in new investments:

  • Portfolio Investment with Le Groupe Maurice (“LGM”): Ventas, in partnership with LGM, a best-in-class, fully integrated designer, developer and operator of senior housing, agreed to invest in a Class-A portfolio of 31 high quality, apartment-like senior housing communities and certain in-progress developments valued at US$1.8 billion in the attractive Quebec market. Key aspects of the partnership, transaction and portfolio include:

    • Expected 5.5 percent stabilized yield on the 31 communities, representing an attractive price. The communities are vibrant and contain top-tier amenities to encourage an active lifestyle. Average length of stay approximates six years.
    • The existing portfolio is comprised of 28 stable communities and three newly constructed lease-up communities. Ventas expects a four percent NOI cumulative average growth rate over the next five years from these 31 communities.
    • Five additional in-progress developments are currently underway, which are expected to be additive to NOI growth. Total expected project costs are C$0.5 billion and targeted stabilized cash yield approximates 6.5 percent.
    • Ventas will have exclusive rights to jointly develop and own all current and future communities under a pipeline agreement with LGM. The Company expects LGM to commence an additional two to three communities per year, consistent with its historical growth.
    • The Quebec senior housing market is compelling, with the senior population expected to double in the next twenty years and the penetration rate for senior housing robust at 18 percent.
    • In June 2019, the Company signed a definitive agreement to acquire the 31 communities and in-progress developments in an 85/15% partnership with the principal of LGM. The portfolio will continue to be managed by LGM.
    • In July 2019, the Company closed the first phase of the acquisition by funding US$723 million to LGM. Completion of the second phase of the investment is expected to occur in the third quarter of 2019, subject to customary closing conditions.
  • R&I Development Pipeline: As part of its pivot to growth, Ventas has announced a $1.5 billion proprietary pipeline of university-based R&I developments with its leading partner, Wexford Science & Technology (“Wexford”). Year-to-date, the Company has announced five specific projects totaling nearly $900 million with top-tier universities. The developments will be utilized for groundbreaking research, academic medicine and innovation. Additionally, the developments are with new and existing Ventas/Wexford university relationships, and establish or expand Knowledge Communities. These five projects include:

    • Pitt Immune Transplant & Therapy Center: Creation of a research, academic medicine and innovation hub anchored by a new relationship with University of Pittsburgh to house cutting-edge immunotherapy research in collaboration with the University of Pittsburgh Medical Center (“UPMC”) and co-located with UPMC’s Shadyside Hospital.
    • One uCity: Expansion of the flourishing Philadelphia uCity Square Knowledge Community associated with the University of Pennsylvania.
    • College of Nursing and Health Professions (“CNHP”), Drexel University: State-of-the-art academic medicine facility, also in uCity Square, which will provide CNHP students, faculty and staff with immediate access to Drexel’s full suite of on-campus resources.
    • Cortex Innovation Tower: Expansion of the vibrant Cortex Innovation Community associated with Washington University in St. Louis.
    • Arizona State University: Class-A, fully lab-enabled research & innovation center anchored by Arizona State University and focused on biomedical discovery and innovation in health outcomes.
    • The above total 1.5 million square feet in aggregate, are approximately 40 percent pre-leased and are expected to generate over a seven percent cash and eight percent GAAP yield, respectively, upon stabilization.
  • Colony Financing: Demonstrating execution consistent with Ventas’s investment framework, including well structured, higher yielding investments, Ventas closed on a $490 million financing to subsidiaries of Colony Capital, Inc. (with its subsidiaries, “Colony”) in June as part of a successful $1.5 billion Colony loan (the “New Colony Loan”). Ventas’s investment bears interest at LIBOR plus 6.4 percent, representing a current all-in cash and GAAP rate of nine percent. The New Colony Loan is supported by a diverse pool of collateral, including 156 U.S. healthcare properties comprised of medical office buildings, senior housing properties and other healthcare assets. Ventas previously held a $282 million tranche of Colony debt that was fully retired with proceeds from the New Colony Loan. Ventas’s investment in the New Colony Loan is expected to add five cents per share of normalized FFO accretion on a full year basis funded on a leverage neutral basis.
  • Duke Health: In June, expanding on the Company’s footprint with Duke University and increasing its investment in academic medicine, Ventas completed an $80 million fee simple acquisition of an asset 100 percent leased for 13 years to Duke University Health System and Duke’s affiliated faculty physician group. Annual cash lease escalators are 2.2 percent. This asset enhances Ventas’s leading MOB portfolio, and extends its relationship with Duke University and Duke School of Medicine, which is an anchor tenant in the Company’s Chesterfield R&I building.

Second Quarter 2019 and Recent Operational and Capital Market Highlights

  • Office Excellence: Ventas’s Office business delivered exceptional performance and achievements year to date:

    • R&I Business Highlights:

      • Validating the robust demand for well-located and designed on-campus research space, Penn Medicine occupied 38,000 square feet of lab space at the Company’s 3711 Market Street, replacing the Science Center, who expanded by leasing 50,000 square feet in the Company’s newly completed building at 3675 Market Street. Both buildings, located in the uCity Knowledge Community in Philadelphia, are now over 97 percent leased.
      • Reinforcing the attractiveness of Ventas’s tenants in its R&I business, Paragon Bioservices, Inc (“Paragon”) a leading life sciences company located in the Company’s University of Maryland, Baltimore Knowledge Community, was recently acquired for $1.2 billion by Catalent Inc. and the Company received $9 million from warrants it held in Paragon equity.
    • MOB Portfolio Recognition: Sutter Van Ness received LEED Gold Certification in the second quarter. Ventas’s trophy 239,000 square foot medical office building development opened in the first quarter of 2019, is currently 83 percent leased, and is anchored by Sutter Health (Moody’s Aa3).
  • Financial Strength Enhanced by Excellent Capital Markets Execution:

    • Ventas’s net debt to adjusted pro forma EBITDA ratio improved sequentially to 5.2x, principally as a result of Ventas equity raised in June in advance of the July closing of the first phase of the LGM transaction.
    • Second quarter and recent activity include:

      • During the second quarter, the Company completed a public offering of common stock for 12.65 million shares that raised $794 million in gross proceeds at an average price of $62.75 per share, principally used to fund the Company’s LGM investment.
      • After the second quarter, the Company issued and sold under its “at the market” equity offering program a total of 1.1 million shares of common stock at an average gross issuance price of $70.41 per share, resulting in nearly $78 million in gross proceeds, used to fund the Company’s investments.
      • After the second quarter, the Company extended its maturity profile and managed interest rate risk via the attractive issuance of $450 million of 2.65% Senior Notes due 2025, proceeds of which were used to retire $397 million of 2.70% Senior Notes due 2020.
    • The Company has robust available liquidity from cash on hand and existing credit facility totaling $2.6 billion at the end of the second quarter 2019, net of outstanding commercial paper.

People & Culture Driving Continued Success

  • Sean P. Nolan Appointed to Board of Directors

    • Sean P. Nolan, former Chief Executive Officer of AveXis, Inc. (formerly NASDAQ: AVXS), a clinical-stage gene therapy company acquired for $8.7 billion in 2018 by Novartis, has been appointed as an independent member of the Company’s Board of Directors, effective immediately. With three decades of extensive experience in the biopharmaceutical industry and a proven track record of business results, Mr. Nolan will contribute unique and complementary insights to enhance the Company’s business, especially its rapidly growing R&I business.
  • Demonstrated Leadership Excellence

    • Robert F. Probst, Ventas Executive Vice President and Chief Financial Officer, was named Financial Executives International’s 2019 Public Company Financial Executive of the Year. The national award is presented annually to a CFO who has made a major impact within their company, achieved success in the company’s growth and profitability, and shown exemplary leadership skills throughout their career.
  • Ventas Named as a Founding Partner of The Global Institute on Innovation Districts (“GIID”)

    • Ventas was named a Founding Partner in GIID, a practitioner-led and empirically grounded not-for-profit organization designed to strategically advance innovation districts worldwide through the creation of a global network and focused research initiatives.

Second Quarter Dividend

The Company paid its second quarter 2019 dividend of $0.7925 per share on July 12, 2019 to stockholders of record on July 1, 2019.

2019 Guidance Improved

After a strong first half of 2019, Ventas is raising its outlook for 2019 per share net income attributable to common stockholders, Nareit FFO and normalized FFO, as described below. The Company also re-affirms its previous overall and segment level same-store cash NOI growth guidance.

 

 

Improved FY 2019 Guidance

 

 

Previous Per Share

 

Current Per Share

 

 

Low

 

High

 

Low

 

High

 

 

 

 

 

 

 

 

 

Net Income Attributable to Common Stockholders

 

$1.23

$1.38

 

$1.38

$1.45

Nareit FFO

 

$3.70

$3.82

 

$3.90

$3.97

Normalized FFO

 

$3.75

$3.85

 

$3.80

$3.86

 

 

 

 

 

 

 

Re-Affirmed-FY 2019 Projected

 

 

 

 

Same-Store Cash NOI Growth Affirmed

 

 

 

 

Low

 

High

 

 

 

 

 

 

 

 

 

NNN

 

0.5%

1.5%

 

 

SHOP

 

(3%)

0%

 

 

Office

 

1.5%

2.5%

 

 

Total Company

 

0%

 

1%

 

 

Assumptions for Ventas’s 2019 improved normalized FFO per share guidance are largely consistent with the Company’s previously disclosed guidance, but now include the impacts of announced investments and associated capital markets activities. In addition, the Company now expects to achieve $600 million of 2019 dispositions and receipt of loan repayments, approximately $360 million of which have occurred to date. Guidance continues to include $0.02 per share in incremental leasing costs from changes in lease accounting standards principally reflected in G&A expenses. The Company’s 2019 outlook now assumes 370 million weighted average fully-diluted shares. Consistent with the Company’s prior statements, the Company’s guidance does not contemplate any modification of its lease with Holiday Retirement. No material unannounced investments or capital activity is included in guidance, except for the Canadian debt financing associated with the closing of the second phase of the LGM transaction.

A reconciliation of the Company’s 2019 guidance to the Company’s projected GAAP measures is included in this press release. The Company’s 2019 guidance is based on a number of other assumptions that are subject to change and many of which are outside the control of the Company. If actual results vary from these assumptions, the Company’s expectations may change. There can be no assurance that the Company will achieve these results.

Second Quarter 2019 Conference Call

Ventas will hold a conference call to discuss this earnings release today at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). The dial-in number for the conference call is (844) 776-7841 (or +1 (661) 378-9542 for international callers), and the participant passcode is “Ventas.” The call will also be webcast live by NASDAQ OMX and can be accessed at the Company’s website at www.ventasreit.com. A replay of the call will be available at the Company’s website, or by calling (855) 859-2056 (or +1 (404) 537-3406 for international callers), passcode 6672539, beginning on July 26, 2019, at approximately 1:00 p.m. Eastern Time and will remain available for 36 days.

Ventas, Inc., an S&P 500 company, is a leading real estate investment trust. Its diverse portfolio of approximately 1,200 assets in the United States, Canada and the United Kingdom consists of senior housing communities, medical office buildings, university-based research and innovation centers, inpatient rehabilitation and long-term acute care facilities, and health systems. Through its Lillibridge subsidiary, Ventas provides management, leasing, marketing, facility development and advisory services to highly rated hospitals and health systems throughout the United States. References to “Ventas” or the “Company” mean Ventas, Inc. and its consolidated subsidiaries unless otherwise expressly noted. More information about Ventas and Lillibridge can be found at www.ventasreit.com and www.lillibridge.com.

The Company routinely announces material information to investors and the marketplace using press releases, Securities and Exchange Commission (“SEC”) filings, public conference calls, webcasts and the Company’s website at www.ventasreit.com/investor-relations. The information that the Company posts to its website may be deemed to be material. Accordingly, the Company encourages investors and others interested in the Company to routinely monitor and review the information that the Company posts on its website, in addition to following the Company’s press releases, SEC filings and public conference calls and webcasts. Supplemental information regarding the Company can be found on the Company’s website under the “Investor Relations” section or at www.ventasreit.com/investor-relations/annual-reports—supplemental-information. A comprehensive listing of the Company’s properties is available at www.ventasreit.com/our-portfolio/properties-by-stateprovince.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding the Company’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, merger or acquisition integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust (“REIT”), plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from the Company’s expectations. The Company does not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made.

The Company’s actual future results and trends may differ materially from expectations depending on a variety of factors discussed in the Company’s filings with the SEC. These factors include without limitation: (a) the ability and willingness of the Company’s tenants, operators, borrowers, managers and other third parties to satisfy their obligations under their respective contractual arrangements with the Company, including, in some cases, their obligations to indemnify, defend and hold harmless the Company from and against various claims, litigation and liabilities; (b) the ability of the Company’s tenants, operators, borrowers and managers to maintain the financial strength and liquidity necessary to satisfy their respective obligations and liabilities to third parties, including without limitation obligations under their existing credit facilities and other indebtedness; (c) the Company’s success in implementing its business strategy and the Company’s ability to identify, underwrite, finance, consummate and integrate diversifying acquisitions and investments; (d) macroeconomic conditions such as a disruption of or lack of access to the capital markets, changes in the debt rating on U.S. government securities, default or delay in payment by the United States of its obligations, and changes in the federal or state budgets resulting in the reduction or nonpayment of Medicare or Medicaid reimbursement rates; (e) the nature and extent of future competition, including new construction in the markets in which the Company’s senior housing communities and office buildings are located; (f) the extent and effect of future or pending healthcare reform and regulation, including cost containment measures and changes in reimbursement policies, procedures and rates; (g) increases in the Company’s borrowing costs as a result of changes in interest rates and other factors, including the potential phasing out of the London Inter-bank Offered Rate after 2021; (h) the ability of the Company’s tenants, operators and managers, as applicable, to comply with laws, rules and regulations in the operation of the Company’s properties, to deliver high-quality services, to attract and retain qualified personnel and to attract residents and patients; (i) changes in general economic conditions or economic conditions in the markets in which the Company may, from time to time, compete, and the effect of those changes on the Company’s revenues, earnings and funding sources; (j) the Company’s ability to pay down, refinance, restructure or extend its indebtedness as it becomes due; (k) the Company’s ability and willingness to maintain its qualification as a REIT in light of economic, market, legal, tax and other considerations; (l) final determination of the Company’s taxable net income for the year ended December 31, 2018 and for the year ending December 31, 2019; (m) the ability and willingness of the Company’s tenants to renew their leases with the Company upon expiration of the leases, the Company’s ability to reposition its properties on the same or better terms in the event of nonrenewal or in the event the Company exercises its right to replace an existing tenant, and obligations, including indemnification obligations, the Company may incur in connection with the replacement of an existing tenant; (n) risks associated with the Company’s senior living operating portfolio, such as factors that can cause volatility in the Company’s operating income and earnings generated by those properties, including without limitation national and regional economic conditions, costs of food, materials, energy, labor and services, employee benefit costs, insurance costs and professional and general liability claims, and the timely delivery of accurate property-level financial results for those properties; (o) changes in exchange rates for any foreign currency in which the Company may, from time to time, conduct business; (p) year-over-year changes in the Consumer Price Index or the UK Retail Price Index and the effect of those changes on the rent escalators contained in the Company’s leases and the Company’s earnings; (q) the Company’s ability and the ability of its tenants, operators, borrowers and managers to obtain and maintain adequate property, liability and other insurance from reputable, financially stable providers; (r) the impact of damage to the Company’s properties from catastrophic weather and other natural events and the physical effects of climate change; (s) the impact of increased operating costs and uninsured professional liability claims on the Company’s liquidity, financial condition and results of operations or that of the Company’s tenants, operators, borrowers and managers, and the ability of the Company and the Company’s tenants, operators, borrowers and managers to accurately estimate the magnitude of those claims; (t) risks associated with the Company’s office building portfolio and operations, including the Company’s ability to successfully design, develop and manage office buildings and to retain key personnel; (u) the ability of the hospitals on or near whose campuses the Company’s medical office buildings are located and their affiliated health systems to remain competitive and financially viable and to attract physicians and physician groups; (v) risks associated with the Company’s investments in joint ventures and unconsolidated entities, including its lack of sole decision-making authority and its reliance on its joint venture partners’ financial condition; (w) the Company’s ability to obtain the financial results expected from its development and redevelopment projects; (x) the impact of market or issuer events on the liquidity or value of the Company’s investments in marketable securities; (y) consolidation activity in the senior housing and healthcare industries resulting in a change of control of, or a competitor’s investment in, one or more of the Company’s tenants, operators, borrowers or managers or significant changes in the senior management of the Company’s tenants, operators, borrowers or managers; (z) the impact of litigation or any financial, accounting, legal or regulatory issues that may affect the Company or its tenants, operators, borrowers or managers; and (aa) changes in accounting principles, or their application or interpretation, and the Company’s ability to make estimates and the assumptions underlying the estimates, which could have an effect on the Company’s earnings.

Contacts

Juan Sanabria

(877) 4-VENTAS

Read full story here

error: Content is protected !!